CDISC has been working diligently on strategy and innovation, thanks to funding from The Leona M. and Harry B. Helmsley Charitable Trust, which invests in critical projects: the development of new data standards for type 1 diabetes (T1D) and Crohn’s disease (CD) research as well as a new set of innovative activities designed to help us move significantly forward in developing the types of standards that can be utilized by non-standards experts. Because of Helmsley’s support, CDISC standards will be opened up as never before to academic researchers, the open source community, and others who can benefit from data standardization and interoperability, but also face a high threshold to implementation of CDISC.
Over time, the newly developed CDISC standards will benefit the T1D and CD communities by allowing more seamless information sharing across research centers as well as improving quality, usefulness, and consistency of clinical data. Once in place, these standards are also expected to provide researchers with the ability to evaluate the effectiveness of emerging treatments. In time, this interoperable data will foster better medical decisions, drug discovery, and healthcare considerations for T1D and CD patients worldwide.